SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

Ryzodeg

NVO·NOVO NORDISK A S
NEUTRAL
Drug Impact Rating2/10
Trial phase
Approved
Time to market
Already approved (2015) but discontinued in the US. Still available in some international markets.
Why 2/10
No hard, dated catalyst is scheduled for Ryzodeg in the next ~12 months. The drug was approved in 2015 and has been discontinued in the US market. It is a legacy product with no pending regulatory decisions, label expansions, or pivotal readouts. For Novo Nordisk (NVO), a DKK 309 billion revenue company driven by GLP-1 products like Ozempic and Wegovy, Ryzodeg is a negligible part of the pipeline.
Actionable Insight NEUTRAL

Ryzodeg is a legacy product with no upcoming catalysts and has been discontinued in the US. For Novo Nordisk (NVO) investors, the drug is not a factor in the investment thesis. Watch NVO's Q3 2026 earnings and the ongoing competitive dynamics between Novo Nordisk's GLP-1 franchise (Ozempic, Wegovy) and Eli Lilly's incretin portfolio instead.

Price Chart

Loading chart...

Executive Summary

Ryzodeg 70/30 is a pre-mixed insulin (70% insulin degludec + 30% insulin aspart) developed by Novo Nordisk. It was FDA-approved in September 2015 for diabetes management in adults and children 1 year and older. However, the product has been discontinued in the United States and is no longer commercially available there, with discontinuations also reported in Australia (February 2025). For Novo Nordisk, a DKK 309 billion revenue company whose growth is overwhelmingly driven by GLP-1 blockbusters (Ozempic, Wegovy), Ryzodeg is a legacy product with no material impact on the stock.

How It Works

Ryzodeg is a pre-mixed insulin shot that combines two types of insulin in one injection: 70% insulin degludec (an ultra-long-acting basal insulin that works slowly and lasts about 24 hours) and 30% insulin aspart (a rapid-acting mealtime insulin that works quickly after eating). This gives patients both background and mealtime blood sugar control in a single daily injection.

Trial Status

Ryzodeg was FDA-approved on September 25, 2015, after an initial Complete Response Letter in February 2013 that required a dedicated cardiovascular outcomes trial (DEVOTE). The resubmission included interim DEVOTE data showing cardiovascular safety. The drug is approved for adults and pediatric patients 1 year of age and older with type 1 or type 2 diabetes. However, the product has been discontinued in the US market and is no longer commercially available there.

The Two-Sided Case

▲ Bull Case3
Ryzodeg remains approved and available in several international markets (e.g., New Zealand, UAE, Australia until recently), providing ongoing revenue in those regions.
The drug offers a convenient once-daily pre-mixed insulin option that combines basal and prandial coverage, which may retain niche demand where still marketed.
Novo Nordisk's dominant position in diabetes care means the company can shift patients to alternative insulin products in its portfolio.
▼ Bear Case4
Ryzodeg has been discontinued in the US market, its largest potential market, and is no longer available to new or existing patients there.
The product faces intense competition from other pre-mixed insulins (NovoLog Mix 70/30, Humalog Mix 75/25) and from the broader shift toward GLP-1 receptor agonists (Ozempic, Mounjaro) for diabetes management.
Discontinuation in Australia (February 2025) and other markets suggests a broader commercial wind-down of the product globally.
For NVO investors, Ryzodeg is immaterial to the investment thesis; the stock's performance depends on GLP-1/obesity franchise dynamics and competitive pressures from Eli Lilly.

Upcoming Catalysts

  • No upcoming catalysts identified. Ryzodeg is a legacy approved product that has been discontinued in the US market.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVO NORDISK A S 6-K NVO ·Originating report

Sources · 12

Hover a chip for the title
1 drugs.com2 drugs.com3 goodrx.com4 accessdata.fda.gov5 accessdata.fda.gov6 pmlive.com7 fda.gov8 attachment.news.eu.nasdaq.com9 emphn.org.au10 tga.gov.au11 stockanalysis.com12 novonordisk.com